drugset / Trial / NCT02229071
Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Phase 1/2
Completed
106 enrolled
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase IB study of donafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, is to assess toxicity,efficacy and pharmacokinetics in patients wiht advanced hepatocellular carcinoma (HCC) .
Timeline
- Start
- 2014-04
- Primary completion
- 2015-12
- Completion
- 2016-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Donafenib | Small molecule | 200 mg | Oral |
| Subject | Donafenib | Small molecule | 300 mg | Oral |